Literature DB >> 18628675

Evidence of depressive symptoms in fragile-X syndrome premutated females.

Laia Rodriguez-Revenga1, Irene Madrigal, Montserrat Alegret, Mónica Santos, Montserrat Milà.   

Abstract

OBJECTIVES: Fragile-X premutation carriers have been considered asymptomatic patients for a long time. It has been, however, demonstrated that the premutation is also involved in clinical pathology, such as premature ovarian failure, the fragile-X-associated tremor/ataxia syndrome, and a distinct neurocognitive and behavioral phenotype, which includes psychiatric problems. To define better this neuropsychiatric phenotype associated with premutation carriers and to minimize a possible environmental effect, we examined psychiatric and depressive symptoms in 34 FMR1 premutation carrier mothers of children with fragile-X syndrome in comparison with two control groups (39 mothers with a non-fragile-X syndrome mentally retarded child and 39 mothers from the general population).
METHODS: All participants completed both questionnaires, which assess psychiatric symptoms (the symptom checklist-90-revised) and depression (Beck Depression Inventory).
RESULTS: Both groups of mothers with a mentally retarded child showed greater susceptibility to psychological problems than the control group without a mentally retarded child, but FMR1 premutated mothers evidenced a higher tendency to depression. These results suggest that, despite the stress of caring for a child with mental retardation, the premutation by itself could be responsible for some psychiatric traits.
CONCLUSION: Our findings reinforce the hypothesis of a pathogenic gene-brain-behavior mechanism in the premutation range.

Entities:  

Mesh:

Year:  2008        PMID: 18628675     DOI: 10.1097/YPG.0b013e3282f97e0b

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  32 in total

1.  Daily health symptoms of mothers of adolescents and adults with fragile x syndrome and mothers of adolescents and adults with autism spectrum disorder.

Authors:  Leann E Smith; Marsha Mailick Seltzer; Jan S Greenberg
Journal:  J Autism Dev Disord       Date:  2012-09

Review 2.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 3.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

4.  Depression in women with spontaneous 46, XX primary ovarian insufficiency.

Authors:  Peter J Schmidt; Jamie A Luff; Nazli A Haq; Vien H Vanderhoof; Deloris E Koziol; Karim A Calis; David R Rubinow; Lawrence M Nelson
Journal:  J Clin Endocrinol Metab       Date:  2010-11-03       Impact factor: 5.958

5.  Conversion disorder in women with the FMR1 premutation.

Authors:  Andreea L Seritan; Andrea Schneider; John M Olichney; Maureen A Leehey; R Scott Akins; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2009-11       Impact factor: 2.802

6.  Ages of Onset of Mood and Anxiety Disorders in Fragile X Premutation Carriers.

Authors:  Andreea L Seritan; James A Bourgeois; Andrea Schneider; Yi Mu; Randi J Hagerman; Danh V Nguyen
Journal:  Curr Psychiatry Rev       Date:  2013-02

7.  Postpartum Depression in Women with the FMR1 Premutation.

Authors:  Roberta W Obadia; Ana-Maria Iosif; Andreea L Seritan
Journal:  Curr Psychiatry Rev       Date:  2013

8.  PSYCHIATRIC DISORDERS ASSOCIATED WITH FXTAS.

Authors:  Andreea L Seritan; Melina Ortigas; Stefan Seritan; James A Bourgeois; Randi J Hagerman
Journal:  Curr Psychiatry Rev       Date:  2013

9.  Clinical phenotypes of a juvenile sibling pair carrying the fragile X premutation.

Authors:  Kirin Basuta; Vivien Narcisa; Alyssa Chavez; Madhur Kumar; Louise Gane; Randi Hagerman; Flora Tassone
Journal:  Am J Med Genet A       Date:  2011-02-22       Impact factor: 2.802

10.  Fragile X and autism: Intertwined at the molecular level leading to targeted treatments.

Authors:  Randi Hagerman; Gry Hoem; Paul Hagerman
Journal:  Mol Autism       Date:  2010-09-21       Impact factor: 7.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.